Sébastien Salas

Assistance Publique Hôpitaux de Marseille — France

Medicine · Health Sciences

42h-index6.7kcitations315works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(82), Soft tissue tumor case studies(44), Cancer Immunotherapy and Biomarkers(42), Head and Neck Cancer Studies(29), Lung Cancer Treatments and Mutations(29)

Publications310 total

Advanced cancer patients’ knowledge and opinions regarding the French law on advance directives: a multicenter cross-sectional study
Supportive Care in Cancer·2026Open Access
Home-based supervised exercise on metastatic cancer patients receiving oral targeted therapy: the AFSOS-Unicancer QUALIOR randomized phase 2 study
The Oncologist·2025Open Access
SChISM: Mechanistic Modeling of cfDNA Fragmentome Dynamics Predicts Progression to Immunotherapy
Zenodo (CERN European Organization for Nuclear Research)·2025Open Access
SChISM: Mechanistic Modeling of cfDNA Fragmentome Dynamics Predicts Progression to Immunotherapy
Zenodo (CERN European Organization for Nuclear Research)·2025Open Access
Corrigendum to “Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)”
Annals of Oncology·2025
Outcome of 1773 superficial non-dermatofibrosarcoma sarcomas A French Sarcoma Group study (FSG) from the NETSARC database
European Journal of Cancer·2025
The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors
ArXiv.org·2025Open Access
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study
Journal of Clinical Oncology·2025· 7 citedOpen Access
2802O Home-based supervised physical activity (SPA) for metastatic cancer patients receiving oral targeted therapy: The AFSOS-Unicancer QUALIOR randomized phase III study
Annals of Oncology·2025
ABS0919 TO COMPARE THE TOLERANCE OF NINTEDANIB IN PATIENTS WITH DIFFUSE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH IMMUNOMEDIATED DISEASES VERSUS PATIENTS WITH DIFFUSE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH NON-IMMUNOMEDIATEDDISEASES IN A MULTIDISCIPLINARY RHEUMATOLOGY-PNEUMOLOGY CONSULTATION
Annals of the Rheumatic Diseases·2025· 1 citedOpen Access
PROPAN: Bayesian dose-finding of propranolol combined with metronomic fixed-dose cyclophosphamide based on bivariate efficacy-tolerability outcomes in patients with locally advanced or metastatic angiosarcoma (LAMA): A phase I-II sequential trial by the French Sarcoma Group.
Journal of Clinical Oncology·2025
Randomized phase II trial evaluating the combination of TG4001, an HPV16 therapeutic vaccine, and avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic (R/M) HPV16-positive cervical or anogenital cancer.
Journal of Clinical Oncology·2025· 2 cited
Early palliative care, intensity of end-of-life care, and their impact on overall survival in cancer patients: A real-world study.
Journal of Clinical Oncology·2025
Abstract 3697: Cell-free DNA fragmentome dynamics as a biomarker for immune-checkpoint inhibition in advanced carcinoma
Cancer Research·2025
Computational Modeling for Circulating Cell-Free DNA in Clinical Oncology
JCO Clinical Cancer Informatics·2025· 2 citedOpen Access
Mechanistic Modeling of cfDNA Fragmentome Dynamics Predicts Progression to Immunotherapy
SPIRE - Sciences Po Institutional REpository·2025Open Access
Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma
CPT Pharmacometrics & Systems Pharmacology·2024· 2 citedOpen Access
Représentations sociales de l’obstination déraisonnable et de l’abandon thérapeutique : démarche comparative auprès des patients hospitalisés en oncologie et des médecins impliqués dans la prise en charge de patients avec un pronostic défavorable.
SPIRE - Sciences Po Institutional REpository·2024
Therapeutic strategy for advanced stages salivary carcinomas of the tongue: A multicenter REFCOR study
Oral Oncology·2024· 1 citedOpen Access
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
Annals of Oncology·2024· 27 citedOpen Access
page 1 of 16Next →

Frequent Co-authors

Jean‐Yves Blay(13), Nicolas Penel(12), François Bertucci(10), Antoîne Italiano(9), Nicolás Isambert(9), Florence Duffaud(9), Sylvie Bonvalot(8), Jean‐Michel Coindre(8), Emmanuelle Bompas(8), Axel Le Cesne(7), Agnès Leroux(6), Karine Baumstarck(6), Pascal Auquier(6), Frédéric Chibon(5), Véronique Brouste(5), Louis Guillou(5), Philippe Terrier(5), Dominique Ranchère‐Vince(5), Christine Chevreau(5), Sophie Piperno‐Neumann(5)